Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal

hapabapa/iStock Editorial via Getty Images 2seventy bio ( NASDAQ: TSVT ) shares popped nearly 4% premarket on Tuesday after it entered a deal to be acquired by Bristol Myers Squibb ( NYSE: BMY ) in an ~$286M all-cash transaction (or $102M net of estimated cash). Bristol Myers Squibb ( NYSE: BMY ) will.